SS-31 (elamipretide) binds cardiolipin in the inner mitochondrial membrane, stabilizing respiratory chain supercomplexes and restoring energy production at the source. FDA-approved for Barth syndrome in 2025, it represents a new category of mitochondrial-targeted therapeutics under active research across cardiac, renal, neurological, and aging models.
